United Therapeutics buys Thymmune Therapeutics

United Therapeutics buys Thymmune Therapeutics
United Therapeutics to buy Miromatrix Medical for $3.25 per share
23.63BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US91307C1027
CUSIP
91307C102
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
20.94
PEG Ratio
2.22
Book Value
148.08
Dividend Share
-
Dividend Yield
-
Earnings Share
26.49
Wall Street Target Price
687.14
EPS Estimate Current Year
24.49
EPS Estimate Next Year
30.53
EPS Estimate Current Quarter
6.0426
EPS Estimate Next Quarter
7.4324
Most Recent Quarter
-
Revenue TTM
3,187,500,032
Gross Profit TTM
2,752,100,096
EBITDA
1,351,299,968
Profit Margin
38.61%
Return On Assets TTM
10.91%
Return On Equity TTM
19.13%
Revenue Per Share TTM
74.085
Qtly Revenue Growth YOY
4.10%
Diluted Eps TTM
26.49
Qtly Earnings Growth YOY
-20.30%
Trailing PE
20.94
Forward PE
17
Price Sales TTM
7.4118
Price Book MRQ
3.7634
Enterprise Value Revenue
6
Enterprise Value EBITDA
12
39.41
2.07%21.84
1.72%9.07
0.06%228.80
0.00%43.05
0.00%11.10
-9.40%155.50
-4.86%31.83
-2.09%43.23
-0.96%95.00
-0.74%